1.
Clinical characteristics of patients in discovery cohort and validation cohort
| Characteristics | Discovery cohort [n (%)] | Validation cohort [n (%)] | Test value | P |
| NCRT, neoadjuvant chemoradiotherapy; *, t value; **, Pearson χ2 value; ***, likelihood ratio. | ||||
Age (
) (year)
|
55.59±9.75 | 58.56±10.32 | 2.065* | 0.040 |
| Gender | 3.296** | 0.069 | ||
| Male | 81 (56.6) | 50 (69.4) | ||
| Female | 62 (43.4) | 22 (30.6) | ||
| Pre-NCRT T-stage | 0.890** | 0.828 | ||
| T2 | 21 (14.7) | 8 (11.1) | ||
| T3 | 106 (74.1) | 55 (76.4) | ||
| T4a | 7 (4.9) | 5 (6.9) | ||
| T4b | 9 (6.3) | 4 (5.6) | ||
| Pre-NCRT N-stage | 9.711*** | 0.084 | ||
| N0 | 9 (6.3) | 6 (8.3) | ||
| N1a | 8 (5.6) | 3 (4.2) | ||
| N1b | 27 (18.9) | 10 (13.9) | ||
| N1c | 0 (0) | 1 (1.4) | ||
| N2a | 36 (25.2) | 9 (12.5) | ||
| N2b | 63 (44.1) | 43 (59.7) | ||
| Pathological T-stage | 2.379*** | 0.666 | ||
| yT0 | 28 (19.6) | 16 (22.2) | ||
| yT1 | 5 (3.5) | 4 (5.6) | ||
| yT2 | 54 (37.8) | 25 (34.7) | ||
| yT3 | 54 (37.8) | 27 (37.5) | ||
| yT4a | 2 (1.4) | 0 (0) | ||
| Pathological N-stage | 3.402*** | 0.638 | ||
| yN0 | 109 (76.2) | 53 (73.6) | ||
| yN1a | 18 (12.6) | 12 (16.7) | ||
| yN1b | 8 (5.6) | 2 (2.8) | ||
| yN1c | 4 (2.8) | 1 (1.4) | ||
| yN2a | 2 (1.4) | 1 (1.4) | ||
| yN2b | 2 (1.4) | 3 (4.2) | ||